Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395)

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):958-9. doi: 10.1016/j.ijrobp.2008.05.070.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy*
  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Carboplatin / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / radiotherapy*
  • Cetuximab
  • Female
  • Humans
  • Male
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Carboplatin
  • Paclitaxel
  • Cetuximab